DiscGenics to Present at 40th Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 6, 2022 /PRNewswire/ -- DiscGenics, Inc., a privately held, clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Chief Executive Officer and Chairman Flagg Flanagan will present at the...
MingMed to Present at the 40th Annual J.P. Morgan Healthcare Conference
GUANGZHOU, China, Jan. 6, 2022 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing First-in-Class pharmaceutical products, today announced that Ms. Liza Ko, Chief Financial Officer of the company, has been invited to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10, 2022 at 08:00 AM ET (09:00 PM, Jan. 10, 2022 Beijing Time),...
Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 6, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th Annual J.P. Morgan Healthcare Conference. Dr. Dajun Yang, Chairman & CEO...
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
NORTH BRUNSWICK, N.J. and HANGZHOU, China, Jan. 6, 2022 /PRNewswire/ -- Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial in the U.S. to evaluate the safety, tolerability, PK and preliminary efficacy of the orally available, small-molecule PD-L1...
Tools4Patient Announces Name Change to Cognivia & Expands Board of Directors
MONT-SAINT-GUIBERT, Belgium, Jan. 5, 2022 /PRNewswire/ -- Cognivia today announced a new name for the company formerly known as Tools4Patient, which provides clinical trials solutions based on AI / ML that account for individual patient personality traits, beliefs and perceptions. The transition to Cognivia more closely reflects the company's mission to "quantify...
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes
MINNEAPOLIS, Jan. 5, 2022 /PRNewswire/ -- Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System. The purpose of the DeLIVER U.S. Study is to establish the safety of liver...
IMG Launches PTOgo, a New Travel Medical Product for Employers and Employees Traveling Abroad
INDIANAPOLIS, Jan. 5, 2022 /PRNewswire/ -- International Medical Group® (IMG®) is excited to introduce PTOgo, a first-of-its-kind travel medical insurance offering for employers and employees that provides accident and sickness coverage for international trips during paid time off. Offered as an employee benefit, PTOgo includes a customizable number of days of travel medical...
ITRI Introduces Health Tech Innovations at CES 2022
HSINCHU, Jan. 5, 2022 /PRNewswire/ -- The Industrial Technology Research Institute (ITRI), Taiwan's largest and one of the world's leading high-tech applied research institutions, today announced it will introduce health technologies at its CES 2022 booth 9513, North Hall, LVCC, and its virtual event site (https://event.itri.org/CES2022). ITRI's health technologies include the PoseFit muscular functional...
Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present at the H.C. Wainwright BIOCONNECT Virtual Conference taking place January 10-13, 2022....
Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation
NEW YORK and SHANGHAI, Jan. 5, 2022 /PRNewswire/ -- Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidates (PCC) for ISM012-077 and ISM012-042 for the treatment of anemia of chronic kidney disease...
